Advertisement
Advertisement
BFRI
Biofrontera Inc. Common Stock
1.22
USDSponsored
+0.01
+0.83%
Aug 11, 15:59 UTC -4
Closed
Pre-Market
1.19
-0.03
-2.46%
BFRI Earnings Reports
Positive Surprise Ratio
BFRI beat 5 of 19 last estimates.
26%
Next Report
Tomorrow BMO
Date of Next Report
Aug 13, 2026
Estimate for Q2 26 (Revenue/ EPS)
$10.71M
/-$0.10
Implied change from Q1 26 (Revenue/ EPS)
+6.21%
/-72.97%
Implied change from Q2 25 (Revenue/ EPS)
+18.60%
/-82.14%
Biofrontera Inc. Common Stock earnings per share and revenue
On May 14, 2026, BFRI reported earnings of -0.37 USD per share (EPS) for Q1 26, missing the estimate of -0.11 USD, resulting in a -215.43% surprise. Revenue reached 10.08 million, compared to an expected 10.46 million, with a -3.55% difference. The market reacted with a +3.00% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.10 USD, with revenue projected to reach 10.71 million USD, implying an decrease of -72.97% EPS, and increase of 6.21% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Liquidia Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
$0.75
Actual
$0.74
Surprise
-2.34%
Mineralys Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.54
Actual
-$2.85
Surprise
-422.26%
Bicara Therapeutics Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.84
Actual
-$0.82
Surprise
+3.18%
Kamada Ltd
Report Date
Aug 12, 2026 For Q2 26
Estimate
$0.11
Actual
$0.16
Surprise
+39.37%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.01
Actual
$0.05
Surprise
+400.00%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.01
Actual
$0.05
Surprise
+595.05%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.37
Actual
-$0.45
Surprise
-20.16%
LENZ Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.02
Surprise
+6.95%
Humacyte, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.16
Surprise
-56.86%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.21
Surprise
-5.58%
FAQ
What were Biofrontera Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Biofrontera Inc. Common Stock reported EPS of -$0.37, missing estimates by -215.43%, and revenue of $10.08M, -3.55% below expectations.
How did the market react to Biofrontera Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 3%, changed from $0.96 before the earnings release to $0.99 the day after.
When is Biofrontera Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 13, 2026.
What are the forecasts for Biofrontera Inc. Common Stock's next earnings report?
Based on 3
analysts, Biofrontera Inc. Common Stock is expected to report EPS of -$0.10 and revenue of $10.71M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement